Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia

Leukemia. 2006 Jan;20(1):142-3. doi: 10.1038/sj.leu.2404029.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Benzamides
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / immunology
  • Child
  • Drug Screening Assays, Antitumor
  • Humans
  • Imatinib Mesylate
  • Immunity, Cellular / drug effects*
  • Immunization
  • Interferon-alpha / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology*

Substances

  • Benzamides
  • Interferon-alpha
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate